Cancer Immunology and Immunotherapy
A section of Cancers (ISSN 2072-6694).
Section Information
Cancer remains a leading cause of death in Western countries, and treatment of advanced stages of the disease is still limited. Discoveries in the field of cancer immunology and progress in immunotherapy as the first line therapy bring the most exciting times for delivering a potential cure for advanced cancer. Understanding the common mechanisms of tumorigenesis, including changes in tumor microenvironment, immune evasion, and antitumor immune responses, is pivotal for further development of novel therapeutics.
Following early discoveries of connection of autoimmune diseases with cancer, recent advances in T cell biology have revolutionized cancer therapy. Most importantly, standard-of-care chemotherapy and radiation effects have also been linked to immune cell-mediated anticancer effects.
Importantly, multiple clinical trials using checkpoint blockade agents, ATC transfer therapies, and cancer vaccines show much better outcomes than the most effective chemotherapeutic agents.
The aim of this Special Section is to publish findings that relate to cancer immunology and therapies based on the immune-targeting. Topics include, but are not limited to:
- checkpoint blockade
- innate immunity
- adaptive responses
- vaccines
- ATC transfer therapy
- immune evasion
- immune switch
- immunosuppression
- tumor microenvironment
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Immune Checkpoint Inhibitors in Cutaneous Oncology (Deadline: 15 October 2023)
- Immunity and Gastrointestinal Cancer (Deadline: 25 October 2023)
- PET/CT in Tumor Immunotherapy Assessment (Deadline: 27 October 2023)
- Advances in Triple-Negative Breast Cancer (Deadline: 30 October 2023)
- Macrophages in Cancer Progression, Diagnosis and Treatment (Deadline: 31 October 2023)
- Unnatural Killers for Immunotherapy: Harnessing NK Cells and Their Diversity in the Tumor Microenvironment (Deadline: 31 October 2023)
- Emerging Trends in Immunotherapy for Triple Negative Breast Cancer (Deadline: 22 November 2023)
- The Role of T/NK Cells in Anti-tumor Immunity (Deadline: 25 November 2023)
- PD-1/PD-L1 Immune Checkpoint Therapy: From Predictive Biomarkers to Noninvasive Imaging (Deadline: 30 November 2023)
- The Role of Extracellular Vesicles (EVs) in Cancer Immunotherapy (Deadline: 30 November 2023)
- Targeted Treatment and Immunotherapy for Hepato-Biliary Tumors (Deadline: 30 November 2023)
- The Role of Immunotherapy in Hematological Malignancies Volume II (Deadline: 30 November 2023)
- Immunotherapy with Checkpoint Inhibitors for Non-small Cell Lung Cancer (Deadline: 30 November 2023)
- Female Malignancies and Immunotherapy: What’s New? (Volume II) (Deadline: 30 November 2023)
- Impact of Carcinogenesis on the Homeostasis of the Host Immune System and Environment in the Lung (Deadline: 30 November 2023)
- Immunometabolism and Cancer: Localized and Systemic Metabolic Interactions That Shape the Evolution of Malignancy (Deadline: 1 December 2023)
- Anti-cancer Vaccines, Adoptive Cell Therapies and Immune-Checkpoint Inhibitors: A Novel Arsenal against Cancer (Deadline: 5 December 2023)
- B Cells and Antibodies in Immune Surveillance and Therapy for Cancer (Deadline: 15 December 2023)
- Mechanisms of Immunosuppression in Cancer (Deadline: 30 December 2023)
- Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma (Deadline: 30 December 2023)
- Anti-tumor Immune Responses: Mechanisms and Escape Mechanisms (Deadline: 31 December 2023)
- Immune Checkpoint Therapy and Biomarker in Cancer (Deadline: 31 December 2023)
- Immune Checkpoint Inhibitors for Urologic Cancers (Deadline: 31 December 2023)
- How to Properly Diagnose and Treat Immune-Related Adverse Events during Immunotherapy in Patients with Cancer: Discussion between Specialists (Deadline: 10 January 2024)
- Oncolytic Viruses: A Key Step toward Cancer Immunotherapy (Deadline: 30 January 2024)
- CDK4/6 Inhibitors in Breast Cancer (Deadline: 31 January 2024)
- Immune-Related Adverse Events in Patients with Cancer: From Bench to Bedside (Deadline: 31 January 2024)
- New Insights into the Complexity of Innate Tumor Immunology: From Basic Concepts to Clinical Application (Deadline: 31 January 2024)
- Precision Immuno-Oncology in NSCLC (Deadline: 8 February 2024)
- New Insights of Hematology in Cancer (Deadline: 15 February 2024)
- Innovative Immunotherapies: CAR-T Cell Therapy for Cancers (Deadline: 29 February 2024)
- Emerging Biomarkers and Therapeutic Targets in Cancer Immunotherapy (Deadline: 29 February 2024)
- Role of Immune Checkpoint Inhibitors or Targeted Therapy in the Treatment of Patients with Melanoma Volume II (Deadline: 29 February 2024)
- The Tumor–Immune Interface for Next-Generation Immunotherapy (Deadline: 8 March 2024)
- Mechanisms of the cGAS-STING Pathway and Their Potential as Novel Targets for Immuno-Oncology (Deadline: 10 March 2024)
- Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors (Deadline: 15 March 2024)
- Immunotherapies and Systems Medicine of Melanoma and Autoimmunity: Recent Advances and Challenges (Deadline: 15 March 2024)
- Utilizing Nanoparticles in Cancer Immunotherapy: Innovations and Challenges (Deadline: 29 March 2024)
- State-of-the-Art Research on Multiple Myeloma Progression (Deadline: 30 March 2024)
- Immunotherapy in the Management of Hematologic Malignancy (Deadline: 30 March 2024)
- Mechanisms of Cancer Cells Escape from Immune Surveillance: The Focus on Epigenetic and Pro-inflammatory Adaptations (Deadline: 31 March 2024)
- CAR T Cells in Lymphoma and Multiple Myeloma (Deadline: 31 March 2024)
- Topical and Intralesional Immunotherapy for Skin Cancer (Deadline: 31 March 2024)
- Oncolytic Viruses as an Emerging Aspect of Immune Oncology (Deadline: 31 March 2024)
- Near-Infrared Photoimmunotherapy for Cancer Treatment (Deadline: 10 April 2024)
- B Cells and Antibody Responses in Cancers (Deadline: 26 April 2024)
- Tumor-Associated Macrophages in Primary Liver Cancers and in Premalignant Liver Diseases (Deadline: 1 May 2024)
- Research Progress of Cutaneous Squamous and Basal Cell Carcinomas (Volume II) (Deadline: 15 May 2024)
- Immunotherapy for Cancers (Deadline: 31 May 2024)
- The Tumor Microenvironment and Molecular Aberrations Convey Immune Evasion (Volume II) (Deadline: 1 June 2024)
- Cancer and Immunomediated Inflammatory Diseases (IMIDs) (Deadline: 10 June 2024)
- State-of-the-Art Cancer Immunology and Immunotherapy in the USA (Deadline: 20 June 2024)
- Diagnosis, Molecular Classification, and Treatment of T-Cell Lymphomas (Deadline: 25 June 2024)
- Immune Checkpoint Inhibitor-Based Immunotherapy in Cancer: Predictive Biomarkers and Mechanisms of Resistance (Deadline: 30 June 2024)
- Clinical and Immunological Therapy for Solid Tumors (Deadline: 30 June 2024)
- Immunosuppression and Protective Immunity in Tumor Microenvironment (Deadline: 30 June 2024)
- Monoclonal Antibodies in Lymphoma (Deadline: 30 June 2024)
- Combination Immunotherapy for Cancer Treatment (Deadline: 30 June 2024)
- Immunotherapy for Multiple Myeloma (Deadline: 15 July 2024)
- Cancer Immunotherapy: Therapeutics and Mechanisms (Deadline: 30 July 2024)
- Cancers Precision Immunotherapy (Deadline: 31 July 2024)
- T Cell and Tumor Immunotherapy (Deadline: 31 July 2024)
- Targeting Immune Checkpoints for Cancer Therapy: Potential and Challenges (Deadline: 15 August 2024)
- Recent Advances in Nanomedicine-Based Cancer Immunotherapy (Deadline: 31 August 2024)
- Immunomodulation in Cancer Treatment (Deadline: 30 September 2024)
- Quantitative Image Tissue Analysis Based on Multiplexed Platforms for Immuno-Oncology Applications (Deadline: 30 November 2024)
Topical Collections
Following topical collections within this section are currently open for submissions:
